XmAb27564 for Psoriasis

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Xencor, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis and atopic dermatitis.

Eligibility Criteria

This trial is for individuals with mild-to-severe plaque psoriasis or moderate-to-severe atopic dermatitis. Participants must weigh between 40 to 150 kg and have not used topical treatments, phototherapy, oral medications, or biologics for their condition within specified time frames before the study starts.

Inclusion Criteria

I am willing and available to follow all study requirements.

I stopped taking oral psoriasis or atopic dermatitis medication 4 weeks ago.

I have plaque psoriasis or atopic dermatitis ranging from mild to severe.

+4 more

Exclusion Criteria

I have asthma, but it has been well controlled for the past 5 years.

You have taken part in a research treatment involving IL-2 therapies before.

Participant Groups

The trial is testing XmAb27564 against a placebo in patients with psoriasis or atopic dermatitis. It aims to assess the safety and how well people tolerate multiple doses of this new medication over a period of time.

2Treatment groups

Experimental Treatment

Group I: Plaque PsoriasisExperimental Treatment2 Interventions

Group II: Atopic DermatitisExperimental Treatment2 Interventions